HD-OPM Archive
Topics › Brain health & dementia

Anti-amyloid antibodies slow early Alzheimer's decline ~30%, with modest benefit and risks

Louis Nervegna · Jun 22, 2026 · ♥ 5 reactions · 4 comments · original Facebook post
Brain health & dementia
AI summary & key facts

Louis shares a JAMA perspective noting that lecanemab and donanemab clear brain amyloid and slow cognitive decline by roughly 30% in early disease, supporting a causal role for amyloid. The effects remain modest and are limited by amyloid-related imaging abnormalities.

Anti-amyloid drugs slow Alzheimer’s decline by about 30% if started early enough.

#alzheimersHD #amyloidHD

Research cited

Shared from JAMA · original post

💬 Perspective by John Hsiao, MD: #AlzheimerDisease diagnosis and treatment have advanced substantially since the unified conceptual framework published in 1976, with major progress in understanding #amyloid-β and tau proteins as central drivers.

Monoclonal antibodies, including #lecanemab and #donanemab, robustly clear brain amyloid-β and slow cognitive decline by approximately 30% in early disease, confirming a causal role for amyloid—though these effects remain modest and are limited by amyloid-related imaging abnormalities.

Current #biomarkers enable staging and preclinical diagnosis, and ongoing trials are testing whether early intervention can prevent #dementia onset.

Paper · JAMA · 2026Stopping Alzheimer DiseaseThis Perspective discusses progress made in Alzheimer disease prevention during the last 50 years.jamanetwork.comNo photo description available.
← newer: Neurologist Perlmutter on what GLP-1 drugs may be doing to tolder: Half of people with fatty liver have normal liver enzymes; F →